This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The mother of four who fell to her death at Purgatory Chasm State Reservation Wednesday afternoon has been identified as Carolyn Sanger of Topsfield, according to the Worcester District Attorney ...

The advantage of Rybelsus is that it is the world’s first ‘peptide (amino acids) in a pill’ and was developed by a revolutionary breakthrough technology. However, Orforglipron is a chemically ...

Due to a security law passed 20 years ago, many Americans are now required to update their driver’s license or identification cards to become REAL ID-compliant — or they won’t be able to ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a diabetes treatment since 2019. It's an orally available version of ...

These undatable men are those who subscribe to the “red pill” notion, an alarming subculture that perpetuates a societal hatred against women by opposing feminist narratives and emphasising ...

The jab averse can now rejoice! Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

A California biotech company has developed a new pill that could extend a dog’s life. After one year of the groundbreaking clinical trial, the pill cleared a major FDA hurdle. More than 1,000 ...

Eli Lilly's experimental oral pill, orforglipron, has shown promising results in Phase 3 trials, effectively lowering weight and blood sugar levels similar to Ozempic in diabetes patients.

FRIDAY, April 18, 2025 (HealthDay News) — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...